The recommendation, included in a health ministry report, calls for the government to vet testing companies and merge their figures with those compiled by public clinics.
For Rocky Swift's latest contributions to The Japan Times, see below:
Already the last major industrial country to start mass vaccinations, Japan is likely to be hampered by a lack of equipment and difficulties in recruiting medical workers.
Japan has arranged to buy 314 million doses, but problems seen in vaccine rollouts elsewhere have stirred doubt that Japan will get those supplies on time.
Tokyo is facing a major regulatory bottleneck due to requirements for local clinical trials before requesting approval for coronavirus shots.
The city of Asahikawa was hit by outbreaks at two major hospitals, exacerbated by subzero temperatures and restricted ventilation that can promote the virus's spread.
Critics say his re-evaluation was too little, too late, and risked leaving the image of a leader both stubborn and indecisive, without due care for public health.
The firm plans to put its vaccine candidate into Phase 1 clinical trials in December and shift into Phase 2 by January.
Japan has become a victim of its own success as slowing new infections have led to a shortage of patients to enroll in trials for treatments and vaccines.
The Osaka-based firm got a headstart in the vaccine development by repurposing its hypertension vaccine, which had already passed various safety hurdles.
Avigan and camostat are undergoing trials as they may be effective in treating illnesses brought on by coronavirus.